Template:Encephalitis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Priyamvada Singh, MBBS [2] ; João André Alves Silva, M.D. [3]
Overview
Encephalitis is an acute inflammation of the brain , commonly caused by a viral infection . Sometimes, encephalitis can result from a bacterial infection, such as bacterial meningitis , or it may be a complication of other infectious diseases like rabies (viral) or syphilis (bacterial). Certainparasitic or protozoal infestations, such as toxoplasmosis , malaria , or primary amoebic meningoencephalitis , can also cause encephalitis in people with compromised immune systems . Treatment with acyclovir with or without steroids and antibiotics should be initiated as soon as possible.[ 1] Antiviral agent like acyclovir has been useful in treatment of encephalitis due to herpes simplex virus and varicella zoster . Treatment for other causative agents of encephalitis is mostly supportive.
Medical Therapy
General Considerations
Reliably tested specific antiviral agents are available only for a few viral agents (e.g. acyclovir or ganciclovir for herpes simplex virus and varicella-zosterencephalitis ). Administer the first dose of acyclovir as soon as possible (in the emergency department itself). Acyclovir can be initiated with or without antibiotics or steroids.The advantages of an early antiviral drug administration are:
Decreases disease duration
Decreases development of latency
Decreases development of complications
Decreases recurrence
Decreases transmission from infected person
Treatment for Toxoplasma gondii and cytomegalovirus encephalitis are available but are used with limited success
Treatment is usually symptomatic. In patients who are very sick, supportive treatment, such as mechanical ventilation , is equally important.
Systemic complications like hypotension , shock , hypoxemia , electrolyte imbalances (hyponatremia , SIADH should be treated promptly.
Neuroimaging with MRI or CT scan should be done before lumbar puncture especially if raised intracranial pressure is suspected.
Lab tests like blood samples should be taken before initiation of therapy.
Bed rest, plenty of fluids and anti-inflammatory drugs to relieve headache and fever should be used.
Empirical Treatment Regimen
Adult & Pediatrics - Acyclovir , 10 mg/kg body weight, 8hourly, intravenous, for 2-3 weeks.
Neonatal HSV - Acyclovir 10-15 mg/kg 8hourly, intravenous, for neonatal HSV
HIV Positive - Foscarnet is generally the treatment of choice given the high incidence of acyclovir resistance in these group of patients.
Treatment for Increased Intracranial Pressure
General
Elevation of head end of the bed
Hyperventilation may be used to decrease intra-cranial pressure on emergency basis
Constant monitoring of neurological status
Avoid increase in intra cranial pressure i.e. control of straining and coughing
Antipyretics and analgesic for fever and pain.
Monitoring and preventing seizures and hypotension .
Drug Therapy
Furosemide 20 mg iv and mannitol 1 gm/kg intravenously for diuresis (blood pressure and CVP should be monitored while administrating these drugs)
Dexamethasone 10mg intravenously 6 hourly to decrease cerebral edema.
Encephalitis Drug Summary
Acyclovir
It is effective for HSV1, HSV2 and varicella zoster.
It is selectively taken up by the body cells infected with HSV and varicella zoster
Prompt treatment with acyclovir is useful in decreasing complications, latency and communicability
Side effects may include nausea, vomiting, diarrhea, loss of appetite, and muscle or joint pain. Rarely, serious adverse effects may include renal and liver functions abnormalities or suppression of bone marrow activity.
Foscarnet
It is effective against HSV 1, HSV 2 and CMV
It is useful in patients who have developed resistance or are non-responders against acyclovir for e.g. HIV positive patients
Drug dosage depends on the renal function of the patient as Foscarnet is excreted through kidneys.
Dexamethasone
It is used in post-infectious and disseminated encephalitis.
It may be used as an adjunct with the antiviral agents
Furosemide
It is used to in encephalitis associated with increased intracranial pressure. The mechanism of action is;
It decreases the production of CSF by inhibiting carbonic anhydrase enzymes.
Decreases cerebral sodium uptake
Inhibits cellular membrane chloride pumps.
The dose should be individualized for patients
Mannitol
Used only on short term basis.
The doses should be individualized based on renal function
Lorazepam
It is used for treatment of seizures associated with encephalitis .
▸ Click on the following categories to expand treatment regimens.
▸ Antimicrobials based on epidemiology/clinic
▸ Rickettsial/ Ehrlichial infection
▸ Acute Disseminated Encephalomyelitis
Suspected encephalitis
Preferred Regimen
▸ Acyclovir 10 mg/kg IV q8h for 14-21 days, in children and adults with normal renal function
▸ Acyclovir 20 mg/kg IV q8h for 21 days, in neonates
Antimicrobials based on epidemiology/clinic
Preferred Regimen
▸ Please refer to Pathogen-based therapy according to epidemiology and clinical evaluation
Rickettsial/ Ehrlichial infection
Preferred Regimen
▸ Acyclovir 10 mg/kg IV q8h in children and adults with normal renal function
▸ Acyclovir 20 mg/kg IV q8h in neonates
PLUS
▸ Doxycycline 200 mg/d in two divided doses
Alternative Regimen
▸ Tetracycline 25-50 mg/kg per day Oral, in four divided doses
Acute Disseminated Encephalomyelitis
Preferred Regimen
▸ Acyclovir 10 mg/kg IV q8h in children and adults with normal renal function
▸ Acyclovir 20 mg/kg IV q8h in neonates
PLUS
▸ Corticosteroids (dexamethasone ) initial 10 mg IV, then 4 mg IM q6h or 2 mg PO 2x-3x/day[ 4]
Pathogen-Based Therapy — Viruses [ 5] [ 3]
▸ Click on the following categories to expand treatment regimens.
▸ Japanese encephalitis virus
▸ St. Louis encephalitis virus
Herpes simplex
Preferred Regimen
▸ Acyclovir 10 mg/kg IV q8h for 14-21 days, in children and adults with normal renal function
▸ Acyclovir 20 mg/kg IV q8h for 21 days, in neonates
Cytomegalovirus
Preferred Regimen
▸ Ganciclovir 5 mg/kg IV q12h for 14-21 days, then valganciclovir 900 mg PO q24h
PLUS
▸ Foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h for 14-21 days; then 90-120 mg/kg IV q24h.
Epstein-Barr virus
Preferred Regimen
▸ Corticosteroids (dexamethasone ) initial 10 mg IV, then 4 mg IM q6h or 2 mg PO 2x-3x/day[ 8]
† May be beneficial, however potential risks must be considered.
Human herpesvirus 6
Preferred Regimen †
▸ Ganciclovir 5 mg/kg IV q12h for 14-21 days
Alternative Regimen †
▸ Foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h for 14-21 days; then 90-120 mg/kg IV q24h.
† Used in immunocompromised patients; no good data on effectiveness in immunocompetent patients.
B virus
Postexposure prophylaxis
▸ Valacyclovir 1 gm PO q8h, for 14 days
OR
▸ Acyclovir 800 mg PO 5x/day, for 14 days
Treatment of disease (Absent CNS symptoms)
▸ Ganciclovir 5 mg/kg IV q12h
OR
▸ Acyclovir 12.5-15 mg/kg IV q8h
Treatment of disease (Presenting CNS symptoms)
▸ Ganciclovir 5 mg/kg IV q12h
Influenza virus
Preferred Regimen
▸ Oseltamivir 75 mg/day, for at least 10 days
Measles virus
Preferred Regimen †
▸ Ribavirin
† Consider intrathecal ribavirin in patients with subacute sclerosing panencephalitis
West Nile virus
Preferred Regimen †
▸
† Ribavirin is not recommended
Japanese encephalitis virus
Preferred Regimen †
▸
† IFN-α is not recommended
St. Louis encephalitis virus
Preferred Regimen
▸ IFN-2α
HIV
Preferred Regimen
▸ HAART
JC virus
Preferred Regimen
▸ Reversal of immunosuppression
OR
▸ HAART †
† In HIV-infected patients
Pathogen-Based Therapy — Bacteria [ 9] [ 3]
▸ Click on the following categories to expand treatment regimens.
▸ Bartonella bacilliformis
▸ Mycobacterium tuberculosis
Rickettsioses and ehrlichioses
▸ Anaplasma phagocytophilum
Bartonella henselae
Preferred Regimen †
▸ Azithromycin Adults: 500 mg PO, 1x, then 250 mg/day PO for 4 days; Children: 10 mg/kg 1x, then 5 mg/kg/day PO for 4 days
Alternative Regimen
▸ Doxycycline 100 mg PO 2x/day for 8 weeks
† With or without Rifampin 300 mg PO 2x/day.
Mycoplasma pnumoniae
Preferred Regimen
▸ Azithromycin 500 mg PO once, then 250 mg 1x/day, for 4 days
Alternative Regimen
▸ Doxycycline 200 mg/day BID PO or IV 1x/day, then 100-200 mg/day qDay or divided q12h PO/IV
OR
▸ Fluoroquinolone 500 mg PO/IV 1x/day, for 7-14 days or 750 mg PO/IV 1x/day, for 5 days
Tropheryma whipplei
Preferred Regimen
▸ Ceftriaxone 1-2 g/day IV/IM 1x/day or divided q12h, for 4-14 days
PLUS
▸ Trimethoprim -Sulfametoxazole 10-20 mg TMP/kg/day IV divided q6-12h
OR
▸ Cefixime 400 mg/day PO 1x/day or divided q12h
Mycobacterium tuberculosis
Preferred Regimen
▸ Isoniazid 300 mgPO qDay, for 9 months
PLUS
▸ Rifampin 10 mg/kg/day PO or 10 mg/kg PO 2x/week (do not exceed 600 mg/day) (DOT)
PLUS
▸ Ethambutol 15 mg/kg PO qDay
PLUS
▸ Pyrazinamide 15-30 mg/kg PO qDay; not exceeding 2 g/day or 50 mg/kg PO 2x/weekly, not exceeding 2 g/dose
PLUS
▸ Dexamethasone 10mg IV q6h†
† Add in patients with meningitis
Anaplasma phagocytophilum
Preferred Regimen
▸ Doxycycline 100 mg PO 2x/day for 30-60 days
Ehrlichia chaffeensis
Preferred Regimen
▸ Doxycycline 100 mg PO 2x/day for 30-60 days
Rickettsia rickettsii
Preferred Regimen
▸ Doxycycline 100 mg PO 2x/day for 30-60 days
Alternative Regimen
▸ Chloramphenicol 50 mg/kg/day IV divided q6hr†
† In certain clinical scenarios (pregnancy )
Coxiella burnetii
Preferred Regimen
▸ Doxycycline 100 mg PO 2x/day for 30-60 days
PLUS
▸ Fluoroquinolone 500 mg PO q12h or 400 mg IV q12h for 10 days
PLUS
▸ Rifampin 600 mg q12hr for 2 days
Treponema pallidum
Preferred Regimen
▸ Penicillin G benzathine 2.4 million units/4mL syringe IM qWeek x3[ 10]
Alternative Regimen
▸ Ceftriaxone 1-2 g/day IV/IM 1x/day or divided q12h, for 4-14 days
Pathogen-Based Therapy — Fungi, Protozoa and Helminths [ 11] [ 3]
▸ Click on the following categories to expand treatment regimens.
▸ Cryptococcus neoformans
▸ Balamuthia mandrillaris
▸ Trypanosoma brucei gambiense
▸ Trypanosoma brucei rhodesiense
▸ Baylisascaris procyonis
Coccidioides species
Preferred Regimen
▸ Fluconazole 400 mg PO on day 1, followed by 200 mg PO qDay
Alternative Regimen
▸ Itraconazole 200 mg PO q8hr for 3-4 days, followed by 200-400 mg/day for at least 3 months
OR
▸ Voriconazole 6 mg/kg IV q12hr for 24 hours, followed by 4 mg/kg IV q12hr or 200 mg PO q12hr
OR
▸ Amphotericin B (IV or Intratechal) start with load dose: 0.25-0.5 mg/kg IV infused over 2-6h, followed by maintenance dose: 0.25-1 mg/kg IV qDay
Cryptococcus neoformans
Preferred Regimen
▸ Amphotericin B start with load dose: 0.25-0.5 mg/kg IV infused over 2-6h, followed by maintenance dose: 0.25-1 mg/kg IV qDay
PLUS
▸ Flucytosine 50-150 mg/kg/day PO divided q6hr
Alternative Regimen
▸ Lipid formulation of amphotericin B 6 mg/kg IV qDay
PLUS
▸ Flucytosine 50-150 mg/kg/day PO divided q6hr
Histoplasma capsulatum
Preferred Regimen
▸ Liposomal Amphotericin B 6 mg/kg IV qDay
PLUS
▸ Itraconazole 200 mg PO q8hr for 3-4 days, followed by 200-400 mg/day for at least 3 months
Acanthamoeba
Preferred Regimen
▸ Trimethoprim -Sulfametoxazole 10-20 mg TMP/kg/day IV divided q6-12h
PLUS
▸ Rifampin 600 mg q12hr for 2 days
PLUS
▸ Ketoconazole 200-400 mg/day PO
Alternative Regimen
▸ Fluconazole 400 mg PO on Day 1, then 200 mg PO qDay
PLUS
▸ Sulfadiazine 1-1.5 g 4x/day, for 3-4 weeks; prophylaxis in HIV patients: 0.5-1 g q6h with pyrimethamine (25-75 mg/day PO) & Folinic acid (10-25 mg/day PO)
PLUS
▸ Pyrimethamine 50-75 mg qDay PO, for 1-3 weeks; then 25-37.5 mg qDay PO for 4-5 weeks
Balamuthia mandrillaris
Preferred Regimen
▸ Pentamidine 2-4 mg/kg IM q24-48hr
PLUS
▸ Macrolide (Azithromycin 500 mg PO once, then 250 mg once daily; or Clarithromycin 500 mg PO q12hr)
PLUS
▸ Fluconazole 400 mg PO on Day 1, then 200 mg PO qDay
PLUS
▸ Sulfadiazine 1-1.5 g 4x/day, for 3-4 weeks; prophylaxis in HIV patients: 0.5-1 g q6h with pyrimethamine (25-75 mg/day PO) & Folinic acid (10-25 mg/day PO)
PLUS
▸ Flucytosine 50-150 mg/kg/day PO divided q6hr
PLUS
▸ Phenothiazine
Naegleria fowleri
Preferred Regimen
▸ Amphotericin B 1.5 mg/kg/day IV divided in 2 doses, for 3 days; then 1 mg/kg/day for 6 days + 1.5 mg/day intrathecal for 2 days; then 1 mg/day intrathecal for 8 days
PLUS
▸ Rifampin 600 mg q12hr for 2 days
Plasmodium falciparum
Preferred Regimen †
▸ Quinine 648 mg PO q8hr, for 3-7 days
OR
▸ Quinidine 300-600 mg or 10 mg/kg PO q8hr, for 5-7 days
OR
▸ Artemether Administer 24 tablets over 3 days: Day 1: 4 tablets initially and 4 tablets after 8h; Day 2 and 3: 4 tablets 2x/day (1 tablet= 20mg/120mg)
Alternative Regimen
▸ Atovaquone -proguanil 1 g/400 mg PO daily, for 3 days
† Exchange transfusion recommended for patients with cerebral malaria or more than 10% parasitemia.
Toxoplasma gondii
Preferred Regimen
▸ Pyrimethamine 50-75 mg qDay PO for 1-3 weeks, then 25-37.5 mg qDay PO for 4-5 weeks
PLUS
▸ Sulfadiazine 1-1.5 g 4x/day, for 3-4 weeks; prophylaxis in HIV patients: 0.5-1 g q6h with pyrimethamine (25-75 mg/day PO) & Folinic acid (10-25 mg/day PO)
OR
▸ Clindamycin 300 mg PO 4x/day, for 6 weeks
Alternative Regimen
▸ Trimethoprim 10 mg/kg/day - Sulfametoxazole 50 mg/kg/day, for 4 weeks
OR
▸ Pyrimethamine 100mg loading dose PO followed by 25-50 mg/day, for 6 weeks
PLUS
▸ Atovaquone 750 mg 2x/day, for 6 weeks
OR
▸ Clarithromycin 500 mg PO q12hr
OR
▸ Azithromycin 500 mg/day, for 6 weeks
OR
▸ Dapsone 100 mg PO qDay
Trypanosoma brucei gambiense
Preferred Regimen
▸ Eflornithine 400 mg/kg/day IV divided 4x/day, for 14 days, then 300 mg/kg/day PO, for 3-4 weeks
Alternative Regimen
▸ Melarsoprol 2-3.6 mg/kg/day IV, for 3 days; after 1 week: 3.6 mg/kg/day IV, for 3 days; then repeat again after 10-21 days: 3.6 mg/kg/day
Trypanosoma brucei rhodesiense
Preferred Regimen
▸ Melarsoprol 2-3.6 mg/kg/day IV for 3 days; then repeat after 7 days; then repeat for 3rd time, 7 days after the 2nd course
Gnathostoma species
Preferred Regimen
▸ Albendazole 400 mg PO q24h or twice a day, for 21 days
OR
▸ Ivermectin 200 μg/kg/day PO, for 2 days
Taenia solium
Preferred Regimen †
▸ Albendazole (more than 60 kgs) 400 mg PO 2x/day, for 8-30 days; (less than 60 kg) 15 mg/kg/day PO divided 2x/day, for 8-30 days; no more than 800 mg/day
PLUS
▸ Corticosteroids
Alternative Regimen
▸ Praziquantel 10-20 mg/kg x1
† Evaluate need for treatment
Pathogen-Based Therapy — Postinfectious or Postvaccination status [ 12] [ 3]
▸ Click on the following categories to expand treatment regimens.
Postinfectious/postvaccination status
▸ Acute disseminated encephalomyelitis
Follow Up Therapy
Physiotherapy
Occupational therapy
Speech therapy
Psychotherapy
References
↑ Whitley RJ (1990). "Viral encephalitis" . The New England Journal of Medicine . 323 (4): 242–50. doi :10.1056/NEJM199007263230406 . PMID 2195341 . Retrieved 2012-02-14 .
↑ Longo, Dan L. (Dan Louis) (2012). Harrison's principles of internal medici . New York: McGraw-Hill. ISBN 978-0-07-174889-6 .
↑ 3.0 3.1 3.2 3.3 3.4 Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL; et al. (2008). "The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America" . Clin Infect Dis . 47 (3): 303–27. doi :10.1086/589747 . PMID 18582201 .
↑ russ. Drug pocket 2011/12 (9th edition ed.). Börm Bruckmeier Publishing. ISBN 978-1-59103-258-8 .
↑ Longo, Dan L. (Dan Louis) (2012). Harrison's principles of internal medici . New York: McGraw-Hill. ISBN 978-0-07-174889-6 .
↑ russ. Drug pocket 2011/12 (9th edition ed.). Börm Bruckmeier Publishing. ISBN 978-1-59103-258-8 .
↑ russ. Drug pocket 2011/12 (9th edition ed.). Börm Bruckmeier Publishing. ISBN 978-1-59103-258-8 .
↑ russ. Drug pocket 2011/12 (9th edition ed.). Börm Bruckmeier Publishing. ISBN 978-1-59103-258-8 .
↑ Longo, Dan L. (Dan Louis) (2012). Harrison's principles of internal medici . New York: McGraw-Hill. ISBN 978-0-07-174889-6 .
↑ 10.0 10.1 Swett C (1975). "Outpatient phenothiazine use and bone marrow depression. A report from the drug epidemiology unit and the Boston collaborative drug surveillance program" . Arch Gen Psychiatry . 32 (11): 1416–8. PMID 978-1-59103-258-8 .
↑ Longo, Dan L. (Dan Louis) (2012). Harrison's principles of internal medici . New York: McGraw-Hill. ISBN 978-0-07-174889-6 .
↑ Longo, Dan L. (Dan Louis) (2012). Harrison's principles of internal medici . New York: McGraw-Hill. ISBN 978-0-07-174889-6 .
Template:WikiDoc Sources